Debilitating reaction following the initial dose of tramadol

Annals of Pharmacotherapy

Volumn 31, Issue 10, 1997, Pages 1150-1152

  Gleason, Patrick P ^a,b   Frye, Reginald F ^a   O'Toole, Thomas ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Tramadol

Indexed keywords

TRAMADOL;

ADULT; ALLERGIC REACTION; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DYSPHORIA; HUMAN; MALE; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; SEROTONIN RELEASE; TREMOR;

EID: 0030961117     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101006     Document Type: Article

References (17)

1. Package insert. Ultram (tramadol). Spring House, PA: McNeil Pharmaceutical, 1995; revised March 1996.
2. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 1993;267:331-40.
3. Barkin RL. Focus on tramadol: a centrally acting analgesic for moderate to moderately severe pain. Formulary 1995;30:321-5.
4. Sunshine A, Olson NZ, Zighelboim I, DeCastro A, Minn FL. Analgesic oral efficacy of tramadol hydrochloride in postoperative pain. Clin Pharmacol Ther 1992;51:740-6.
5. Mehlisch DR, Brown P, Letner A, Minn F. Tramadol hydrochloride: short term efficacy in pain following dental surgery (abstract). Presented at the 94th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther 1993;53:223.
6. Rauck RL, Ruoff GE, McMillen JI. Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res 1994;55:1417-31.
7. Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996;101(suppl 1A):47S-53S.
8. Parr WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Invest 1992;70:708-10.
9. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/ sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
10. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
11. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-9.
12. Liao S, Hill JF, Nayak RK. Pharmacokinetics of tramadol following single and multiple oral doses in man (abstract). Pharm Res 1992;9(suppl 10):308.
13. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104.
14. Frye RF, Branch RA. Improved high performance liquid Chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. J Chromatogr B 1996;677:178-82.
15. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488-93.
16. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5.
17. Poulsen L, Arendt-Nielson L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60: 636-44.